Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT00006025
Phase
PHASE1
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrent malignant glioma.

Key Dates

Start date
Jan 5, 2001
Status verified
Jun 2018
Primary completion
Jan 10, 2005
Completion
Dec 1, 2007

Study Design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (9)

FacilityCityStateZIPSite coordinators
Jonsson Comprehensive Cancer Center, UCLALos AngelesCalifornia90095-
UCSF Comprehensive Cancer CenterSan FranciscoCalifornia94143-
Warren Grant Magnuson Clinical Center - NCI Clinical Studies SupportBethesdaMaryland20892-1182-
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer InstituteBostonMassachusetts02115-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10021-
Hillman Cancer Center at University of Pittsburgh Cancer InstitutePittsburghPennsylvania15232-
University of Texas - MD Anderson Cancer CenterHoustonTexas77030-4009-
University of Texas Health Science Center at San AntonioSan AntonioTexas78284-6220-
University of Wisconsin Comprehensive Cancer CenterMadisonWisconsin53792-

Find similar trials in Los Angeles, CA

By research site
Jonsson Comprehensive Cancer Center, UCLA· Los Angeles, CAUCSF Comprehensive Cancer Center· San Francisco, CAWarren Grant Magnuson Clinical Center - NCI Clinical Studies Support· Bethesda, MDDana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute· Boston, MAMemorial Sloan-Kettering Cancer Center· New York, NYHillman Cancer Center at University of Pittsburgh Cancer Institute· Pittsburgh, PA

Related Studies